{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-009377","form_type":"8-K","ticker":null,"cik":"0001825367","company_name":"RayzeBio, Inc.","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.765627+00:00","generated_at":"2026-06-05T15:40:21.472029+00:00","sec_items":["1.02","2.01","5.03","3.01","3.03","5.01","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Bristol-Myers Squibb completes acquisition of RayzeBio for $62.50 per share in cash","bullets":["Bristol-Myers Squibb acquired RayzeBio at $62.50/share; 53,052,499 shares tendered (~86% of outstanding).","Merger effective Feb 26, 2024; all outstanding shares converted to right to receive $62.50 cash per share.","Stock options fully vested and cashed out for excess of $62.50 over exercise price.","All directors resigned; new directors from Bristol-Myers appointed; executive officers replaced.","Company to delist from Nasdaq and file Form 15 to terminate SEC reporting obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-009377","json":"https://secwatch.observer/filing/0001140361-24-009377.json","markdown":"https://secwatch.observer/filing/0001140361-24-009377.md","text":"https://secwatch.observer/filing/0001140361-24-009377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/ef20022333_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T15:40:21.472029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"217c53a261","claim":"Mary Tagliaferri resigned as Director at RayzeBio, Inc..","evidence_excerpt":"each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"278669eaf1","claim":"Benjamin Hickey was appointed as President at RayzeBio, Inc..","evidence_excerpt":"Benjamin Hickey was appointed to serve as President of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"2ce35db49c","claim":"Sophia Park was appointed as Vice President at RayzeBio, Inc..","evidence_excerpt":"Sophia Park was appointed to serve as a Vice President of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Vice President"}],"fact_type":"executive_change"},{"claim_id":"471c81b68f","claim":"Ken Song resigned as Director at RayzeBio, Inc..","evidence_excerpt":"each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4b7f53ae25","claim":"Angie You resigned as Director at RayzeBio, Inc..","evidence_excerpt":"each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7a4530bd17","claim":"Tim Van Hauwermeiren resigned as Director at RayzeBio, Inc..","evidence_excerpt":"each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"91274614ad","claim":"Sandra Ramos-Alves was appointed as Director at RayzeBio, Inc..","evidence_excerpt":"the directors of Purchaser as of immediately prior to the Effective Time, which consisted of Konstantina Katcheves, Sandra Ramos-Alves and Kimberly M. Jablonski, became the directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"became director"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"918d97ccfa","claim":"Scott Matarese was appointed as Vice President at RayzeBio, Inc..","evidence_excerpt":"Scott Matarese was appointed to serve as a Vice President of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Vice President"}],"fact_type":"executive_change"},{"claim_id":"a284e30e90","claim":"Richard Heyman resigned as Director at RayzeBio, Inc..","evidence_excerpt":"each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a8462ed9bc","claim":"Christy Oliger resigned as Director at RayzeBio, Inc..","evidence_excerpt":"each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"bb0c16ef2b","claim":"Kimberly M. Jablonski was appointed as Director at RayzeBio, Inc..","evidence_excerpt":"the directors of Purchaser as of immediately prior to the Effective Time, which consisted of Konstantina Katcheves, Sandra Ramos-Alves and Kimberly M. Jablonski, became the directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"became director"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"bea1ba1cdb","claim":"Sandra Ramos-Alves was appointed as Vice President and Treasurer at RayzeBio, Inc..","evidence_excerpt":"Sandra Ramos-Alves was appointed to serve as a Vice President and Treasurer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Vice President and Treasurer"}],"fact_type":"executive_change"},{"claim_id":"d3aff01334","claim":"Konstantina Katcheves was appointed as Director at RayzeBio, Inc..","evidence_excerpt":"the directors of Purchaser as of immediately prior to the Effective Time, which consisted of Konstantina Katcheves, Sandra Ramos-Alves and Kimberly M. Jablonski, became the directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"became director"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"dc2b9e98a7","claim":"Yi Larson resigned as Director at RayzeBio, Inc..","evidence_excerpt":"each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e3efaf37a6","claim":"Kimberly M. Jablonski was appointed as Vice President and Secretary at RayzeBio, Inc..","evidence_excerpt":"Kimberly M. Jablonski was appointed to serve as a Vice President and Secretary of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Vice President and Secretary"}],"fact_type":"executive_change"},{"claim_id":"ed2cd9cb63","claim":"Maha Katabi resigned as Director at RayzeBio, Inc..","evidence_excerpt":"each of Richard Heyman, PhD, Tim Van Hauwermeiren, Maha Katabi, PhD, Yi Larson, Christy Oliger, Ken Song, MD, Mary Tagliaferri, MD, and Angie You, PhD resigned as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"afeaa797e3a0516732fd0b1a1658e385b17a4377","claim":"RayzeBio, Inc.: Bylaws amended and restated in their entirety pursuant to Merger Agreement at Effective Time.","evidence_excerpt":"the Company’s certificate of incorporation and bylaws were amended and restated in their entirety, as set forth in Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"bd3821a62bb5bc3e57b3c97ba54ee57911fe7770","claim":"RayzeBio, Inc.: Certificate of incorporation amended and restated in its entirety pursuant to Merger Agreement at Effective Time.","evidence_excerpt":"the Company’s certificate of incorporation and bylaws were amended and restated in their entirety, as set forth in Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"94aad5e35a35ba8e38b46c2ca2832de09988b6d6","claim":"RayzeBio, Inc. underwent a change of control involving Bristol-Myers Squibb Company for $62.50 per Share in cash (closed 2024-02-26).","evidence_excerpt":"Purchaser commenced a tender offer to acquire all of the outstanding shares of common stock of the Company, par value $0.0001 per share (the “ Shares ”), at an offer price of $62.50 per Share in cash (the “ Offer Price ”), without interest, subject to any applicable withholding of taxes, upon the terms and subject to the conditions set forth in the Offer to","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1825367/000114036124009377/0001140361-24-009377-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Bristol-Myers Squibb Company"},{"label":"Consideration","value":"$62.50 per Share in cash"},{"label":"Closing","value":"2024-02-26"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}